{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:15:29Z","timestamp":1781374529483,"version":"3.54.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cjca.2014.02.011","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T23:17:59Z","timestamp":1393370279000},"page":"534-543","source":"Crossref","is-referenced-by-count":107,"title":["Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome"],"prefix":"10.1016","volume":"30","author":[{"given":"Heather Yvonne","family":"Small","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto C.","family":"Montezano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian M.","family":"Touyz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2014.02.011_bib1","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1172\/JCI70212","article-title":"Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer","volume":"123","author":"Welti","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2014.02.011_bib2","doi-asserted-by":"crossref","first-page":"a006452","DOI":"10.1101\/cshperspect.a006452","article-title":"VEGF-directed blood vessel patterning: from cells to organism","volume":"2","author":"Bautch","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2174\/156800911795655985","article-title":"VEGF\/VEGFR pathway inhibitors as anti-angiogenic agents: present and future","volume":"11","author":"Sharma","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.cjca.2014.02.011_bib4","doi-asserted-by":"crossref","first-page":"a006593","DOI":"10.1101\/cshperspect.a006593","article-title":"The VEGF pathway in cancer and disease: responses, resistance, and the path forward","volume":"2","author":"Kieran","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cjca.2014.02.011_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/17512433.2014.862496","article-title":"Novel tyrosine kinase inhibitors for renal cell carcinoma","volume":"7","author":"Dorff","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cjca.2014.02.011_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A\u00a0randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12094-012-0985-x","article-title":"Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor","volume":"15","author":"Afonso","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canep.2012.11.001","article-title":"Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors","volume":"37","author":"Dreyfus","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.cjca.2014.02.011_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.cjca.2014.02.011_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1634\/theoncologist.2010-0271","article-title":"Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review","volume":"16","author":"Keefe","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.cjca.2014.02.011_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jch.12052","article-title":"Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors","volume":"15","author":"Caro","year":"2013","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjca.2014.02.011_bib14","doi-asserted-by":"crossref","first-page":"e39580","DOI":"10.1371\/journal.pone.0039580","article-title":"Chronic VEGF blockade worsens glomerular injury in the remnant kidney model","volume":"7","author":"Machado","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2014.02.011_bib15","first-page":"267","article-title":"Kidney injury during VEGF inhibitor therapy","volume":"70","author":"den Deurwaarder","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000334458","article-title":"Antiangiogenic-induced hypertension: the molecular basis of signaling network","volume":"73","author":"Nagai","year":"2012","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.cjca.2014.02.011_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjca.2014.02.011_bib18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacc.2012.01.069","article-title":"\u201cOn-target\u201d cardiac effects of anticancer drugs: lessons from new biology","volume":"60","author":"Simons","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.02.011_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11523-009-0106-0","article-title":"Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors","volume":"4","author":"Snider","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib20","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.cjca.2014.02.011_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/FPC.0b013e3283364ed7","article-title":"Vascular endothelial growth factor pathway","volume":"20","author":"Maitland","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cjca.2014.02.011_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2011.03.012","article-title":"Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis","volume":"131","author":"Larsen","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cjca.2014.02.011_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/1538574408322755","article-title":"Current insights on the biology and clinical aspects of VEGF regulation","volume":"42","author":"Birk","year":"2008","journal-title":"Vasc Endovasc Surg"},{"key":"10.1016\/j.cjca.2014.02.011_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cjca.2014.02.011_bib25","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","article-title":"Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1","volume":"16","author":"Forsythe","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cjca.2014.02.011_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2045-824X-5-17","article-title":"Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis","volume":"5","author":"Hernandez","year":"2013","journal-title":"Vasc Cell"},{"key":"10.1016\/j.cjca.2014.02.011_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MNH.0b013e3283361c24","article-title":"Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension","volume":"19","author":"Yogi","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.cjca.2014.02.011_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/BJ20110301","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"437","author":"Koch","year":"2011","journal-title":"Biochem J"},{"key":"10.1016\/j.cjca.2014.02.011_bib30","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1091\/mbc.E07-05-0467","article-title":"Src-mediated phosphorylation of hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase","volume":"18","author":"Duval","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.cjca.2014.02.011_bib31","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1074\/jbc.M412017200","article-title":"Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer","volume":"280","author":"Neagoe","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cjca.2014.02.011_bib32","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood-2008-12-196584","article-title":"Phosphorylation of endothelial nitric oxide synthase by atypical PKC zeta contributes to angiopoietin-1-dependent inhibition of VEGF-induced endothelial permeability in\u00a0vitro","volume":"114","author":"Oubaha","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2014.02.011_bib33","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00432-011-1049-2","article-title":"PI3K\/Akt and MAPK\/ERK1\/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer","volume":"137","author":"Zhu","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/10623320600697955","article-title":"Vascular endothelial growth factor (VEGF)-receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E","volume":"13","author":"Shibuya","year":"2006","journal-title":"Endothelium"},{"key":"10.1016\/j.cjca.2014.02.011_bib35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1089\/ars.2007.1556","article-title":"VEGF signaling through NADPH oxidase-derived ROS","volume":"9","author":"Ushio-Fukai","year":"2007","journal-title":"Antiox Redox Signal"},{"key":"10.1016\/j.cjca.2014.02.011_bib36","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/j.freeradbiomed.2012.10.546","article-title":"Nox4- and Nox2-dependent oxidant production is required for VEGF-induced SERCA cysteine-674 S-glutathiolation and endothelial cell migration","volume":"53","author":"Evangelista","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","article-title":"Vascular endothelial growth factor (VEGF) and its receptors","volume":"13","author":"Neufeld","year":"1999","journal-title":"FASEB J"},{"key":"10.1016\/j.cjca.2014.02.011_bib38","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.febslet.2013.05.038","article-title":"VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing","volume":"587","author":"Saito","year":"2013","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cjca.2014.02.011_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/cvr\/cvq105","article-title":"Vascular endothelial growth factors and vascular permeability","volume":"87","author":"Bates","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2014.02.011_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/hr.2011.175","article-title":"Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF","volume":"35","author":"Nako","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cjca.2014.02.011_bib41","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1073\/pnas.0703577104","article-title":"Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions","volume":"104","author":"Advani","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2014.02.011_bib42","first-page":"329","article-title":"Angiogenesis, metastasis, and lung cancer. An overview","volume":"74","author":"Onn","year":"2003","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1040-8428(00)00062-7","article-title":"Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis","volume":"34","author":"Gerwins","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cjca.2014.02.011_bib44","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2014.02.011_bib45","doi-asserted-by":"crossref","first-page":"a006577","DOI":"10.1101\/cshperspect.a006577","article-title":"Anti-VEGF therapies in the clinic","volume":"2","author":"Meadows","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib46","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1158\/1078-0432.CCR-09-1717","article-title":"Rapid development of hypertension by sorafenib: toxicity or target?","volume":"15","author":"Humphreys","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2014.02.011_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-013-2124-y","article-title":"Anti-vascular endothelial growth factor therapy in the era of personalized medicine","volume":"72","author":"F\u00e9liz","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cjca.2014.02.011_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.cjca.2014.02.011_bib49","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12197","article-title":"Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors","volume":"104","author":"Niwakawa","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cjca.2014.02.011_bib50","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s10637-012-9796-8","article-title":"Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities","volume":"30","author":"Cohen","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cjca.2014.02.011_bib51","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cjca.2014.02.011_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2125.2012.04197.x","article-title":"Model-based treatment optimization of a novel VEGFR inhibitor","volume":"74","author":"Keizer","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2014.02.011_bib53","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.02.011_bib54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11523-011-0204-7","article-title":"Cardiovascular toxicity of anti-angiogenic drugs","volume":"6","author":"des Guetz","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40261-014-0174-5","article-title":"Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis","volume":"34","author":"Qi","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cjca.2014.02.011_bib56","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40261-013-0125-6","article-title":"Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials","volume":"33","author":"Dai","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cjca.2014.02.011_bib57","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.cjca.2014.02.011_bib58","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/annonc\/mdq221","article-title":"Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24","volume":"21","author":"Goodwin","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2014.02.011_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2040-7378-5-7","article-title":"Anti-vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study","volume":"5","author":"Reimann","year":"2013","journal-title":"Exp Transl Stroke Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10456-004-2699-3","article-title":"Angiogenic growth factors and hypertension","volume":"7","author":"Sane","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cjca.2014.02.011_bib63","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1093\/annonc\/mdq767","article-title":"Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors","volume":"22","author":"Langenberg","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib64","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2217\/fon.12.73","article-title":"Cediranib: a VEGF receptor tyrosine kinase inhibitor","volume":"8","author":"Sahade","year":"2012","journal-title":"Future Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib65","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2215\/CJN.08111109","article-title":"Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor","volume":"5","author":"Robinson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2014.02.011_bib66","first-page":"819546","article-title":"An association between bevacizumab and recurrent posterior reversible encephalopathy syndrome in a patient presenting with deep vein thrombosis: a case report and review of the literature","volume":"2012","author":"Lazarus","year":"2012","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.cjca.2014.02.011_bib67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jcpt.12031","article-title":"Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma","volume":"38","author":"Asaithambi","year":"2013","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cjca.2014.02.011_bib68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-011-0201-x","article-title":"Posterior reversible encephalopathy syndrome induced by anti-VEGF agents","volume":"6","author":"Tlemsani","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib69","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/B978-0-7020-4088-7.00109-7","article-title":"Posterior reversible encephalopathy syndrome","volume":"121","author":"Lamy","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.cjca.2014.02.011_bib70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425255.2012.656845","article-title":"Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy","volume":"8","author":"Horsley","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cjca.2014.02.011_bib71","first-page":"503","article-title":"Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension","volume":"92","author":"Eechoute","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2014.02.011_bib72","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib73","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors","volume":"56","author":"Robinson","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.02.011_bib74","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/157016112800812836","article-title":"Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies","volume":"10","author":"Ferroni","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.cjca.2014.02.011_bib75","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.02.011_bib76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.110.168120","article-title":"Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans","volume":"58","author":"Mayer","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.02.011_bib77","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1158\/0008-5472.CAN-09-3722","article-title":"Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cjca.2014.02.011_bib78","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.02.011_bib79","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib80","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/ars.2013.5244","article-title":"Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress","volume":"20","author":"Lankhorst","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.cjca.2014.02.011_bib81","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/HJH.0b013e32835c1d1b","article-title":"Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1","volume":"31","author":"Lankhorst","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.02.011_bib82","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jacc.2012.02.053","article-title":"Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer","volume":"60","author":"Belcik","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.02.011_bib83","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11906-011-0206-y","article-title":"Mechanisms of antiangiogenic-induced arterial hypertension","volume":"13","author":"Mourad","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cjca.2014.02.011_bib84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2008.02.044","article-title":"Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy","volume":"266","author":"Ushio-Fukai","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cjca.2014.02.011_bib85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.02.011_bib86","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.02.011_bib87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2011.37.1195","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors","volume":"30","author":"Schutz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib88","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.02.011_bib89","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1053\/j.seminoncol.2013.09.010","article-title":"Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management","volume":"40","author":"Steingart","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clcc.2011.03.021","article-title":"An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition","volume":"10","author":"Copur","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.cjca.2014.02.011_bib91","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cjca.2014.02.011_bib92","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1440-1681.2012.05699.x","article-title":"Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib","volume":"39","author":"Nagasawa","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cjca.2014.02.011_bib93","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cjca.2014.02.011_bib94","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3747\/co.19.972","article-title":"Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents","volume":"19","author":"Larochelle","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib95","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2014.02.011_bib96","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10456-012-9327-4","article-title":"Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension","volume":"16","author":"Kruzliak","year":"2013","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cjca.2014.02.011_bib97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ajh\/hpt201","article-title":"Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors","volume":"27","author":"Kruzliak","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.02.011_bib98","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1073\/pnas.1203275109","article-title":"Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition","volume":"109","author":"Sunshine","year":"2012","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14001056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14001056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T23:50:42Z","timestamp":1565221842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X14001056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0828282X14001056"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2014.02.011","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}